| Literature DB >> 29552044 |
Maryam Ghadiri1, Ebrahim Vasheghani-Farahani1, Fatemeh Atyabi2, Farzad Kobarfard3, Hossein Hosseinkhani4.
Abstract
Cationic polymeric nanoparticles have great potential for developing drug delivery systems with limited side effects for tumor medication. The goal of this research is investigation of cationic dextran-spermine polymer (DS) efficacy for improvement of hydrophilic drug delivery to negatively charged cancerous cells. Capecitabine (as a hydrophilic antineoplastic drug) was loaded into the magnetic dextran-spermine nanoparticles (DS-NPs) via ionic gelation. Design of experiments was applied to specify how the significant factors affect size, surface charge and capecitabine entrapment efficiency of the DS-NPs. Physicochemical properties, in-vitro release profile and cellular studies of the optimized DS-NPs were evaluated. The experimental results indicated that DS-NPs with favorable properties can be achieved at an optimized condition of 2 mg/mL DS and 0.75 mg/mL tri-polyphosphate (TPP) concentrations, TPP addition rate of 35 mL/min, pH 3 of DS solution and super paramagnetic iron oxide nanoparticles (SPION)/DS mass ratio of 0.5. The entrapment efficiency of capecitabine was 26.1% at optimum condition and drug release at neutral pH after 24 h and acidic pH within 3 h was 56 and 98%, respectively. The cytotoxicity assessment exhibited that capecitabine loaded DS-NPs was more toxic than corresponding free drug as control. Significant cellular uptake of capecitabine loaded DS-NPs by U87MG glioblastoma cells were proved by Prussian blue staining and TEM, qualitatively. DS-NPs are suitable candidates for delivery of the hydrophilic drugs in cancer treatment and due to positive charge of the dextran-spermine, the uptake of the hydrophilic drugs by the cancerous cells was improved.Entities:
Keywords: Cancer; Controlled release; Drug delivery systems; Factorial design; U87MG
Year: 2017 PMID: 29552044 PMCID: PMC5843296
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Figure 1Chemical structure of dextran-spermine (a) and capecitabine (b); schematic diagram for preparation of capecitabine loaded magnetic dextran-spermine nanoparticles (DS-NPs) (c) and H-NMR spectra of synthesized dextran-spermine (d
Levels of the factors used in experimental design for preparation of capecitabine loaded DS-NPs according to the half fractional factorial 2 (5-1) design.
|
|
|
| |
|---|---|---|---|
|
|
| ||
| A- Dextran-spermine Conc. (DS) | mg/mL | 2.00 | 4.00 |
| B- TPP Conc. (TPP) | mg/mL | 0.50 | 1.00 |
| C- TPP Addition rate (Rate) | mL/min | 35.00 | 60.00 |
| D- pH (pH) | - | 3.00 | 5.00 |
| E- SPION/DS mass ratio (SPION/DS) | - | 0.50 | 0.75 |
A- Dextran-spermine concentration (DS); B- Tri-polyphosphate concentration (TPP); C- Tri-polyphosphate addition rate (Rate); D- pH of dextran-spermine solution (pH); E- Super paramagnetic iron oxide nanoparticle/dextran-spermine mass ratio (SPION/DS).
Responses values for particle size (nm), zeta potential (mV) and entrapment efficiency (%) of DS-NPs according to the half fractional factorial 2 (5-1) design
|
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| ||
| S1 | - - - - + | 2.00 | 0.50 | 35.00 | 3.00 | 0.75 | 76 | +37.90 | 13.23 |
| S2 | + - - - - | 4.00 | 0.50 | 35.00 | 3.00 | 0.50 | 64 | +35.50 | 12.92 |
| S3 | - + - - - | 2.00 | 1.00 | 35.00 | 3.00 | 0.50 | 96 | +15.00 | 27.13 |
| S4 | + + - - + | 4.00 | 1.00 | 35.00 | 3.00 | 0.75 | 77 | +33.30 | 20.15 |
| S5 | - - + - - | 2.00 | 0.50 | 60.00 | 3.00 | 0.50 | 72 | +20.30 | 10.55 |
| S6 | + - + - + | 4.00 | 0.50 | 60.00 | 3.00 | 0.75 | 72 | +32.40 | 15.70 |
| S7 | - + + - + | 2.00 | 1.00 | 60.00 | 3.00 | 0.75 | 100 | +19.40 | 17.89 |
| S8 | + + + - - | 4.00 | 1.00 | 60.00 | 3.00 | 0.50 | 76 | +24.40 | 11.35 |
| S9 | - - - + - | 2.00 | 0.50 | 35.00 | 5.00 | 0.50 | 99 | +17.50 | 26.12 |
| S10 | + - - + + | 4.00 | 0.50 | 35.00 | 5.00 | 0.75 | 80 | +33.90 | 14.49 |
| S11 | - + - + + | 2.00 | 1.00 | 35.00 | 5.00 | 0.75 | 183 | +18.20 | 11.37 |
| S12 | + + - + - | 4.00 | 1.00 | 35.00 | 5.00 | 0.50 | 139 | +24.10 | 23.28 |
| S13 | - - + + + | 2.00 | 0.50 | 60.00 | 5.00 | 0.75 | 117 | +20.80 | 17.04 |
| S14 | + - + + - | 4.00 | 0.50 | 60.00 | 5.00 | 0.50 | 83 | +39.60 | 9.38 |
| S15 | - + + + - | 2.00 | 1.00 | 60.00 | 5.00 | 0.50 | 135 | +10.20 | 22.80 |
| S16 | + + + + + | 4.00 | 1.00 | 60.00 | 5.00 | 0.75 | 80 | +31.60 | 17.59 |
| S17 | 0 0 0 0 0 | 3.00 | 0.75 | 47.50 | 4.00 | 0.63 | 90 | +32.80 | 11.19 |
| S18 | 0 0 0 0 0 | 3.00 | 0.75 | 47.50 | 4.00 | 0.63 | 89 | +29.67 | 17.98 |
| S19 | 0 0 0 0 0 | 3.00 | 0.75 | 47.50 | 4.00 | 0.63 | 96 | +25.78 | 16.97 |
A- Dextran-spermine concentration (DS); B- tripolyphosphate concentration (TPP); C- tripolyphosphate addition rate (Rate); D- pH of dextran-spermine solution (pH); E- Super paramagnetic iron oxide nanoparticle/dextran-spermine mass ratio (SPION/DS); Particle size (PS); Zeta potential (ZP); Entrapment efficiency (EE).
Characteristics of fitted model to the responses
|
|
|
|
|
|
|---|---|---|---|---|
| EE (%) | 0.0059 | 0.91 | 0.79 | Insignificant ( |
| PS (nm) | 0.0002 | 0.99 | 0.96 | Insignificant ( |
| ZP (mV) | 0.0019 | 0.94 | 0.84 | Insignificant ( |
EE: Entrapment efficiency; PS: Particle size; ZP: Zeta potential.
Figure 2Pareto chart of the effective factors on the entrapment efficiency of capecitabine in cationic polymeric nanoparticles (a); Pareto chart of the factors affecting in particle size of capecitabine loaded cationic polymeric nanoparticles (b); Pareto chart of the factors affecting in zeta potential of capecitabine loaded cationic polymeric nanoparticles (c
Comparison between predicted and experimental values for the optimal formulation of capecitabine loaded DS-NPs
|
|
|
| |
|---|---|---|---|
| Predicted | 23.43 | 73 | +22.5 |
| Experimental | 26.09 | 79 | +22.8 |
| Absolute relative deviation | 11.35% | 8.22% | 1.33% |
EE: Entrapment Efficiency; PS: Particle Size; ZP: Zeta Potential.
Figure 3FT-IR spectra of dextran-spermine, DS-NPs and SPIONs (a); SEM (b) and TEM (c) images of capecitabine loaded DS-NPs; Size and the polydispersity of DS-NPs measured by DLS (d
Figure 4.The magnetic behavior (VSM) of SPIONs and DS-NPs (300 K
Figure 5Release profile of capecitabine from cationic dextran-spermine nanoparticles in two: (□) acidic (pH 4.8) and (◊) neutral (pH 7.4) media
Figure 6Viability of U87MG cells determined by MTT assay after incubation with neat DS-NPs (▪), free capecitabine (▲) and capecitabine loaded DS-NPs (●) at different concentrations of capecitabine (0-160 µM) for 24 h (a) and 48 h (b) (n = 3); Prussian blue staining images of U87MG cells after 14 h incubation with control group (c) and capecitabine loaded DS-NPs (d) at concentration of 0.1 µg/mL; TEM image of U87MG cells fixed after incubation with DS-NPs (e